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5-Hydroxydecanoate is metabolised in mitochondria
and creates a rate-limiting bottleneck for β-oxidation
of fatty acids
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5-Hydroxydecanoate (5-HD) blocks pharmacological and ischaemic preconditioning, and
has been postulated to be a specific inhibitor of mitochondrial ATP-sensitive K+ (KATP)
channels. However, recent work has shown that 5-HD is activated to 5-hydroxydecanoyl-CoA
(5-HD-CoA), which is a substrate for the first step of β-oxidation. We have now
analysed the complete β-oxidation of 5-HD-CoA using specially synthesised (and purified)
substrates and enzymes, as well as isolated rat liver and heart mitochondria, and compared
it with the metabolism of the physiological substrate decanoyl-CoA. At the second step of
β-oxidation, catalysed by enoyl-CoA hydratase, enzyme kinetics were similar using either
decenoyl-CoA or 5-hydroxydecenoyl-CoA as substrate. The last two steps were investigated
using l-3-hydroxyacyl-CoA dehydrogenase (HAD) coupled to 3-ketoacyl-CoA thiolase. V max
for the metabolite of 5-HD (3,5-dihydroxydecanoyl-CoA) was fivefold slower than for the
corresponding metabolite of decanoate (L-3-hydroxydecanoyl-CoA). The slower kinetics were
not due to accumulation of D-3-hydroxyoctanoyl-CoA since this enantiomer did not inhibit
HAD. Molecular modelling of HAD complexed with 3,5-dihydroxydecanoyl-CoA suggested
that the 5-hydroxyl group could decrease HAD turnover rate by interacting with critical
side chains. Consistent with the kinetic data, 5-hydroxydecanoyl-CoA alone acted as a
weak substrate in isolated mitochondria, whereas addition of 100 µM 5-HD-CoA inhibited
the metabolism of decanoyl-CoA or lauryl-carnitine. In conclusion, 5-HD is activated,
transported into mitochondria and metabolised via β-oxidation, albeit with rate-limiting
kinetics at the penultimate step. This creates a bottleneck for β-oxidation of fatty acids. The
complex metabolic effects of 5-HD invalidate the use of 5-HD as a blocker of mitochondrial
KATP channels in studies of preconditioning.
(Received 15 August 2004; accepted after revision 25 October 2004; first published online 25 October 2004)
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The phenomenon of preconditioning, whereby short
ischaemic or pharmacological interventions transiently
protect the heart from infarction following a sub-
sequent prolonged period of ischaemia, is of considerable
clinical interest (Yellon & Downey, 2003). Despite
enormous research efforts in the past one to two decades,
the molecular and cellular mechanisms underlying
preconditioning have not been conclusively identified.
Recently, mitochondrial ATP-sensitive K+ (KATP) channels
have been implicated as important mediators of
preconditioning (Garlid et al. 2003; Gross & Peart, 2003;
Yellon & Downey, 2003; O’Rourke, 2004). However, the
evidence for their role in preconditioning is primarily
based on the effects of pharmacological agents, in
particular, diazoxide and 5-hydroxydecanoate (5-HD).
Diazoxide was reported to be a specific opener of
mitochondrial KATP channels (Garlid et al. 1996), but
recent studies have suggested that its mechanism of
cardioprotection may be due to other actions, such as
inhibition of succinate dehydrogenase (Hanley et al.
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2002a; Lim et al. 2002), activation of sarcolemmal KATP
channels (Suzuki et al. 2003) or transient opening of the
mitochondrial permeability transition pore (Hausenloy
et al. 2004).
Elucidating the action of 5-HD may provide a
key to understanding the mechanisms involved in
cardioprotection, since it blocks nearly all forms
of preconditioning. Several years ago, 5-HD was
deduced to be a specific blocker of mitochondrial
KATP channels (Jaburek et al. 1998). More recent work
has shown that the situation is much more complex
since we now know that 5-HD, like other fatty acid
substrates, is activated via acyl-CoA synthetase, yielding
5-hydroxydecanoyl-CoA (5-HD-CoA) (Hanley et al.
2002a; Lim et al. 2002). Following extramitochondrial
activation, acyl-CoA esters are taken up into
mitochondria via carnitine palmitoyltransferases (CPT-I
and CPT-II) and carnitine acylcarnitine translocase
(Bartlett & Eaton, 2004), but, at this stage, it is not
clear whether 5-HD-CoA can be transported via this
system. Using isolated heart and liver mitochondria,
Lim et al. (2002) reported that 5-HD acted either
as a weak substrate or inhibited metabolism, and
they suggested that 5-HD-CoA could not access the
matrix.
Once in the matrix, acyl-CoA esters are sequentially
oxidised and shortened by two carbon atoms via
the β-oxidation pathway, such that decanoyl-CoA
would be shortened to octanoyl-CoA after one
round, and 5-HD-CoA would be shortened to
3-hydroxyoctanoyl-CoA (that is, the 5-hydroxyl group
would become a 3-hydroxyl group). It should be
noted that metabolism of racemic 5-HD-CoA will
give rise to two different enantiomers of the products,
and the extent to which the different enantiomers
are metabolised by the downstream enzymes is not
known. Thus, l-3-hydroxyoctanoyl-CoA, formed
after one round of 5-HD-CoA β-oxidation, could be
metabolised normally, whereas the other enantiomer
(d-3-hydroxyoctanoyl-CoA) could exert an inhibitory
effect on β-oxidation. In a recent paper (Hanley et al.
2003), we have shown that activated 5-HD, similar to
decanoyl-CoA, is a good substrate for purified human
liver (as well as pig kidney) medium-chain acyl-CoA
dehydrogenase, the first step of β-oxidation. In the
present study, we provide a comprehensive analysis of the
metabolism of 5-HD via the subsequent three steps of
β-oxidation. Some of the results have been published in
preliminary form (Hanley et al. 2004).
Methods
Enzymes of the β-oxidation pathway
Activity of enoyl-CoA hydratase (EC 4.2.1.17), which
catalyses the hydration of enoyl-CoA esters, was assayed
spectrophotometrically. In each assay, 0.5 µg bovine
liver enoyl-CoA hydratase (Fluka) was added to a
1 ml cuvette and absorbance changes were measured at
263 nm. Recombinant human heart l-3-hydroxyacyl-CoA
dehydrogenase (HAD; EC 1.1.1.35) was expressed and
purified as previously described (Barycki et al. 2000).
HAD catalyses the oxidation of the l-3-hydroxyl group to a
keto group concomitant with the reduction of
NAD+. Purified pig-heart 3-ketoacyl-CoA thiolase
(3-ketothiolase), the ultimate enzyme of β-oxidation,
was kindly provided by Professor Horst Schulz (City
University of New York, NY, USA). Unless stated
otherwise, HAD was assayed indirectly by coupling it
to the 3-ketothiolase reaction, which circumvented the
problem of product inhibition (Noyes & Bradshaw, 1973;
He et al. 1989). The coupled assay mixture contained
2.78 µg HAD, 0.5 mm NAD+, 0.25 mm CoASH and 0.4 µg
3-ketothiolase. Absorbance changes were measured at
340 nm. All experiments using the aforementioned
enzymes were performed at 25◦C in standard solution
containing 50 mm potassium phosphate, 0.3 mm EDTA
and 10% glycerol (pH 7.6). Titrations were performed
in duplicate. In separate experiments, free coenzyme A
(CoASH) concentration was determined at various time
intervals using DTNB (5,5′-dithiobis-(2-nitrobenzoic
acid)) (Hanley et al. 2003).
Synthesis and purification of β-oxidation
intermediates
5-HD-CoA was synthesised essentially as previously
described (Hanley et al. 2003). In brief, acyl-CoA
synthetase (EC 6.2.1.3; Sigma) was used to
synthesise 5-HD-CoA from 5-HD and CoASH in
tris(hydroxymethyl)aminomethane (Tris) buffer solution
containing (mm): 1.2 Na2ATP, 100 Tris, 9.1 EDTA
and 1.8 EDTA (pH 7.5 with HCl). The enoyl-CoA
esters decenoyl-CoA and 5-hydroxydecenoyl-CoA
(5-HD-enoyl-CoA) were prepared enzymatically using
human liver medium-chain acyl-CoA dehydrogenase
and ferricenium hexafluorophosphate (Kumar &
Srivastava, 1994). Finally, l-3-hydroxydecanoyl-CoA and
3,5-dihydroxydecanoyl-CoA were synthesised from their
respective enoyl-CoA esters using bovine liver enoyl-CoA
hydratase. The various decanoyl-CoA and 5-HD-CoA
derivatives were purified by preparative reversed-phase
HPLC.
Synthesis of pure D- and L-3-hydroxyoctanoyl-CoA
esters
Racemic 3-hydroxyoctanoyl-CoA was prepared
by reacting CoASH with a 1.2-fold excess of
3-hydroxyoctanoyl-imidazole in 4 ml of tetrahydro-
furan/125 mm NaHCO3 (1:1, v/v), in accord with
the method of acyl-CoA ester synthesis described by
C© The Physiological Society 2004
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Kawaguchi et al. (1981). The imidazole derivative was
obtained by adding 3-hydroxyoctanoic acid (Larodan
Fine Chemicals AB, Malmo¨, Sweden) to a 1.3-fold excess
of 1,1-carbonyldiimidazole in tetrahydrofuran. After
evaporation of the solvent, the residue was dissolved in
ethylacetate and washed with 3 N H3PO4, 0.75 N H3PO4
and finally with water, before being dried. Analysis by
thin layer chromatography (TLC) revealed a single spot
(retention factor (Rf) 0.78). The CoA-ester reaction was
allowed to proceed for 6 h, then dried down, dissolved
in 8 ml 1 m NaCl and distributed over four C18-SPE
(solid-phase extraction) cartridges (1 g), activated with
methanol and equilibrated with 1 m NaCl. Cartridges
were washed with 1 m NaCl, 0.5 m NaCl and water, and
eluted with increasing concentrations of acetonitrile in
water.
The enantiomers of 3-hydroxyoctanoyl-CoA were
prepared from octanoyl-CoA by the combined action
of acyl-CoA oxidase with either peroxisomal l-specific
multifunctional protein (MFP1) or peroxisomal d-specific
multifunctional protein (MFP2). The multifunctional
proteins were isolated as previously described (Novikov
et al. 1994). Octanoyl-CoA (5 µmol; P-L Biochemicals,
Milwaukee, WI, USA) was desaturated at 30◦C with
0.5 U acyl-CoA oxidase (Arthrobacter species; Sigma)
in 10 ml reaction mixture, which contained 100 mm
potassium phosphate buffer (pH 7.5), 5 µm FAD and
5 U ml−1 catalase. Upon completion (∼40 min; monitored
at 280 nm; ε = 3.6), multifunctional proteins were
added (either 12.6 µg MFP1 or 5.4 µg MFP2) and
disappearance of the 2-enoyl-CoA was monitored at
280 nm. After reaching equilibrium (∼60 min), reaction
mixtures were loaded on activated C18-SPE cartridges
(500 mg; Waters). Cartridges were washed with 2 m
ammonium acetate and the CoA-esters were eluted with
methanol/water (80:20) containing 10 mm ammonium
acetate. After evaporation of the solvent under reduced
pressure, the samples were purified by preparative
reversed-phase HPLC. Major peaks were collected,
and those corresponding to 3-hydroxyoctanoyl-CoA
(and remaining 2-octenoyl-CoA) were evaporated and
lyophilised (the yield for 3-hydroxyoctanoyl-CoA esters
was ∼55%).
Analytical reversed-phase HPLC revealed a single
peak for the isolated 3-hydroxyoctanoyl-CoA isomers,
whereas a small contaminant (4.9%) was present in
the racemic CoA-ester. Further tests showed that the
isolated 3-l-hydroxyoctanoyl-CoA was dehydrogenated
in the presence of NAD+ to 3-oxooctanoyl-CoA by
purified MFP1, but not by MFP2. The d-isomer was
a substrate for MFP2 but not for MFP1, confirming
that the pure isomers had been assigned the correct
configurations. The racemic compound was converted by
both enzymes.
Molecular modelling
A structure of HAD in complex with NAD+ and
3-keto-octanoyl-CoA (1.8 A

, R = 20.1%, Rfree = 23.1%; J.
J. Barycki and L. J. Banaszak, unpublished data) was used
as a template for the modelling studies. To generate a
model of 3,5-dihydroxydecanoyl-CoA bound to the active
site, a hydroxyl group at position C5 of the substrate
was modelled in both the d and l configurations, and
two additional carbon atoms were added to the acyl
chain using the program O (Jones et al. 1991). Minor
arrangements of adjacent amino acid side chains were
required to accommodate 3,5-dihydroxydecanoyl-CoA in
the active site of the enzyme, but typically, displacements
were less than 0.2 A

.
Isolated liver and heart mitochondria
Coupled mitochondria were isolated from rat liver as
previously described (Johnson & Lardy, 1967; Brandt et al.
1992), and suspended in solution containing 250 mm
sucrose, 2 mm Tris and 1 mm EDTA (pH 7.4). Heart
mitochondria were isolated along the lines described
by Jacobus & Saks (1982). Diced ventricular tissue was
minced and washed with a solution containing 300 mm
sucrose, 10 mm Hepes and 0.2 mm EDTA (pH 7.2).
The tissue was treated with trypsin (∼0.1 mg ml−1)
for 15 min, and twice homogenised before adding
soybean trypsin inhibitor (∼0.3 mg ml−1). The heart
mitochondria were subsequently washed, centrifuged
and resuspended in solution containing 300 mm
sucrose, 10 mm Hepes, 0.2 mm EDTA and 1 mg ml−1
bovine serum albumin (pH 7.4). The isolation was
performed at 4◦C.
The rate of respiration was monitored at 25◦C
using an Oxygraph-2 k system (Oroboros, Innsbruck,
Austria) with DatLab software. Mitochondria, used
at a final concentration of 1.4–1.6 mg ml−1 (liver) or
∼0.2 mg ml−1 (heart), were added to buffer containing
various concentrations of sucrose and (mm): 10 potassium
phosphate, 10 Tris-HCl, 10 MgSO4 and 2 EDTA
(pH 7.4). Substrates were tested in the presence of
0.5 mm malate (in heart and selected liver experiments),
0.5 mm ADP and, in the case of acyl-CoA esters
(decanoyl-CoA, lauryl-CoA, oleoyl-CoA and 5-HD-CoA),
0.13–0.2 mm l-carnitine. Unless stated otherwise, the
free fatty acids were added in the absence of ATP
and CoASH, which are required for extramitochondrial
activation.
The mitochondria had respiratory control ratios
of 5–6 with 65 mm sucrose in the buffer solution
(low osmolar conditions). At high osmolarity (440 mm
sucrose), the respiratory control ratio was higher (∼10),
largely due to the lower basal activity under these
conditions.
C© The Physiological Society 2004
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Statistical analysis
An ANOVA was used to determine statistical significance
at the 0.95 level of confidence. Data are expressed as
means ± s.e.m.
Figure 1. Kinetics of 5-hydroxydecanoyl-CoA (5-HD-CoA)
metabolism at the second step of β-oxidation
A, the hydratase-catalysed reaction. B and C, steady-state activity of
bovine liver enoyl-CoA hydratase, determined at various
concentrations of decenoyl-CoA (B) or 5-hydroxydecenoyl-CoA
(C). Data were fitted using the Michaelis–Menten equation.
Results
Kinetics of 5-HD-enoyl-CoA and decenoyl-CoA
metabolism
The substituted fatty acid 5-HD is widely used to block
preconditioning. To clarify its mechanism of action
we studied the metabolism of 5-HD by mitochondrial
enzymes and compared it to the metabolism of the
physiological substrate decanoate. The second step
of β-oxidation is catalysed by enoyl-CoA hydratase
(Fig. 1A). The kinetics of this reaction were determined
using various concentrations of purified decenoyl-CoA
(Fig. 1B) or 5-HD-enoyl-CoA (Fig. 1C). When
decenoyl-CoA was used as substrate, a K m of 4.1 ± 0.3 µm
and a V max of 21.7 ± 0.5 µm min−1 were obtained.
In accord, K m values in the range 3–8 µm have been
previously reported for the decenoyl-CoA dependent
hydratase reaction (Yang et al. 1985; Jiang et al. 1996).
We found that enzyme kinetics were similar when
5-HD-enoyl-CoA was used as substrate; hydratase
catalysed the hydration of 5-HD-enoyl-CoA (yielding
3,5-dihydroxydecanoyl-CoA) with a K m of 12.7 ± 0.6 µm
and a V max of 25.7 ± 0.5 µm min−1. This observation,
together with the recent data of Hanley et al. (2003),
indicates that 5-HD-CoA can be efficiently metabolised
via the first two steps of the β-oxidation pathway, that is,
medium-chain acyl-CoA dehydrogenase and enoyl-CoA
hydratase.
We next tested whether 5-HD-CoA was
metabolised via the last two steps of β-oxidation
(Fig. 2A) catalysed by l-3-hydroxyacyl-CoA
dehydrogenase (HAD) and l-3-ketoacyl-CoA
thiolase (3-ketothiolase). In preliminary experiments
(not shown) we found that addition of
90 µm 5-HD-enoyl-CoA stimulated HAD activity, albeit
to a lesser extent than addition of 90 µm decenoyl-CoA.
Addition of 3-ketothiolase shifted the reaction
equilibrium to the right, indicating that 5-HD-CoA can
be metabolised via all four enzymes of the β-oxidation
pathway. Free CoASH concentration was reduced
from 100 µm to 27 µm (maximal rate, 17 µm min−1)
when l-3-hydroxydecanoyl-CoA was used in the assay.
In comparison, free CoASH concentration was only
reduced from 100 µm to 63 µm (maximal rate,
1 µm min−1) when 3,5-dihydroxydecanoyl-CoA was
used as substrate.
As shown in Fig. 2B and C, there was a striking
difference in the kinetics of the HAD-thiolase catalysed
reactions when 3,5-dihydroxydecanoyl-CoA rather
than l-3-hydroxydecanoyl-CoA was used as the
substrate. With the naturally occurring substrate
l-3-hydroxydecanoyl-CoA, HAD had a K m of
7.5 ± 0.6 µm and a V max of 40.3 ± 1.2 µm min−1 (Fig. 2B),
whereas with 3,5-dihydroxydecanoyl-CoA (Fig. 2C), the
K m was about two times higher (12.6 ± 1.1 µm) and V max
C© The Physiological Society 2004
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was considerably slower (7.7 ± 0.2 µm min−1). To shed
light on the mechanism by which the 5-hydroxyl group of
3,5-dihydroxydecanoyl-CoA slowed kinetics at HAD, we
used a molecular model based on X-ray crystallographic
data.
Figure 2. Kinetics of 5-HD-CoA metabolism at the last two steps
of β-oxidation
A, the sequential reactions catalysed by L-3-hydroxyacyl-CoA
dehydrogenase (HAD) and 3-ketoacyl-CoA thiolase (3-ketothiolase). B
and C, kinetics of the coupled HAD-3-ketothiolase reactions
determined as a function of the concentrations of
3-hydroxydecanoyl-CoA or 3,5-dihydroxydecanoyl-CoA.
Molecular modelling of HAD–substrate complexes
Figure 3 shows NAD+ and 3,5-dihydroxydecanoyl-CoA
bound to the active site of HAD. Note that the carbon
at position 3 is modelled in an sp2 configuration, as
was observed in previously described structures of
HAD in complex with either 3-hydroxybutyryl-CoA
or acetoacetyl-CoA (Barycki et al. 2000). In the
l configuration, the C5 hydroxyl group would be
located between V212 and another active site residue,
N208 (Fig. 3). It is important to note that the exact
configuration of the side chain of N208 cannot be
assigned unequivocally. The d configuration (hydroxyl
on left; Fig. 3) would have a tighter fit. The hydroxyl
group would be wedged between the side chains of
I261 and the active site serine, S137, which is critical
for activity.
D-3-Hydroxyoctanoyl-CoA does not inhibit HAD
When racemic 5-HD-CoA enters the β-oxidation
pathway, and becomes shortened by two carbon atoms
at the ultimate step, l-3-hydroxyoctanoyl-CoA and
d-3-hydroxyoctanoyl-CoA should emerge. The l-isomer
is a normal substrate for HAD, whereas the d-isomer is
not a normal substrate for the enantiospecific enzyme
HAD, and may even inhibit this enzyme. In order
to test this possibility, we synthesised pure isomers of
3-hydroxyoctanoyl-CoA. Figure 4 shows that the l-isomer
was good substrate for human heart HAD (Fig. 4A),
whereas the d-isomer did not stimulate enzyme activity
(Fig. 4B). More importantly, the presence of the d-isomer
did not inhibit HAD-catalysed oxidation of the l-isomer
(Fig. 4C).
Figure 3. Model of HAD in complex with NAD+ and
3,5-dihydroxydecanoyl-CoA
The hydroxyl group at C5 is depicted in both the D (nearest to NAD+)
and in the L configuration. Oxygen atoms are shown in red, nitrogen
in blue, phosphorus in purple and sulphur in yellow.
C© The Physiological Society 2004
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Metabolism of 5-HD and 5-HD-CoA
by rat liver mitochondria
Oxidation of free fatty acids in the presence of respiring
mitochondria was studied in the absence of ATP and
Figure 4. D-3-Hydroxyoctanoyl-CoA is neither a substrate nor
an inhibitor of HAD
A, the pure isomer L-3-hydroxyoctanoyl-CoA (40 µM) was a good
substrate for the human heart HAD (open circle, lower trace). In
parallel experiments, 3-ketoacyl-CoA thiolase was added to
circumvent product inhibition of HAD (filled circle, upper trace). B, the
pure isomer D-3-hydroxyoctanoyl-CoA (40 µM) did not act as substrate
for HAD (even at concentrations as high as 400 µM; not shown).
C, the presence of D-3-hydroxyoctanoyl-CoA (40 µM) did not inhibit
HAD-catalysed oxidation of L-3-hydroxyoctanoyl-CoA (40 µM).
CoASH so that their respective CoA-esters could not
be synthesised at the mitochondrial outer membrane.
To optimise fatty acid oxidation, a solution with low
osmolarity (115 mosmol l−1) was used (Halestrap &
Dunlop, 1986; Halestrap, 1987). Addition of decanoate
to coupled mitochondria potently stimulated state 3
respiration by a factor of between five and six (Fig. 5A),
whereas 5-HD evoked a much weaker response (Fig. 5B).
The addition of 0.5 mm malate did not affect the rate
of respiration stimulated by 5-HD (not shown). Our
observations are consistent with the data of Lim et al.
(2002) and indicate that 5-HD can be activated in the
matrix. At high osmolarity (490 mosmol l−1), neither
decanoate nor 5-HD stimulated respiration (not shown),
consistent with the earlier work (Otto & Ontko, 1982;
Halestrap & Dunlop, 1986; Halestrap, 1987).
To test whether extramitochondrially synthesised
5-HD-CoA can enter mitochondria via carnitine
palmitoyltransferases, we added purified 5-HD-CoA
as substrate to isolated mitochondria. As expected,
decanoyl-CoA (or oleoyl-CoA; not shown), strongly
stimulated oxygen consumption in the presence of ADP
(state 3) (Fig. 5C). 5-HD-CoA also stimulated state 3
respiration (Fig. 5D), indicating that 5-HD-CoA is indeed
a substrate for the carnitine-dependent acyl-transfer
system.
Metabolism of 5-HD-CoA, but not 5-HD,
by rat heart mitochondria
In preliminary experiments using heart mitochondria,
we found that malate stimulated the rate of metabolism
of medium-chain acyl-CoA esters and medium-chain
acyl-carnitine; therefore, we performed all subsequent
experiments in the presence of 0.5 mm malate. Figure 6A
shows that decanoate strongly stimulated state 3
respiration in heart mitochondria in the absence of
l-carnitine, suggesting that it is readily activated in
the matrix. Under the same conditions, 5-HD did not
stimulate respiration (Fig. 6B), suggesting that it is a poor
substrate for heart-type matrix acyl-CoA synthetase.
On the other hand, both decanoyl-CoA (Fig. 6C) and
5-HD-CoA (Fig. 6D) were significantly metabolizsd
by heart mitochondria (as was the case with liver
mitochondria; Fig. 5D). However, in the presence of
5-HD-CoA, the maximal rate of oxygen consumption of
heart mitochondria was about threefold slower than with
decanoyl-CoA.
5-HD-CoA acts both as substrate and inhibitor
of β-oxidation
The slow kinetics of 5-HD-CoA metabolism at HAD
(Fig. 2C) suggested that it could act both as substrate
and as an inhibitor of the β-oxidation pathway. To test
this possibility, we examined the effect of 5-HD-CoA
C© The Physiological Society 2004
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on respiration supported by decanoyl-CoA (Fig. 7A).
Addition of decanoyl-CoA (10 µm) strongly stimulated
respiration, but when, in addition, 5-HD-CoA (100 µm)
was present, the maximal rate was reduced by ∼40%. In
principle, 5-HD-CoA could limit the rate of decanoyl-CoA
metabolism by either decreasing its rate of uptake into
the matrix (via CPT-I/CPT-II) and/or by attenuating
the activity of matrix enzymes. In support of the
latter possibility, the metabolism of lauryl-carnitine
(C12-carnitine), downstream of CPT-I, was similarly




5-HD reliably blocks all forms of preconditioning, and has
been assumed to be a specific blocker of mitochondrial
KATP channels. In fact, blockage by 5-HD was often used
as evidence for the involvement of mitochondrial KATP
channels. In the present study, we have shown at the
level of individual enzymes and in intact mitochondria
Figure 5. Metabolism of decanoate,
5-hydroxydecanoate (5-HD) and their
CoA esters by liver mitochondria
A and B, effects of decanoate or
5-hydroxydecanoate on the rate of
oxygen consumption of coupled rat liver
mitochondria in the presence of 0.5 mM
ADP, but in the absence of ATP and
CoASH. Note the lower rate of oxygen
consumption when 5-HD was the
substrate. At least n = 3 experiments
were performed at each concentration.
C and D, effects of decanoyl-CoA and
5-HD-CoA on the rate of oxygen
consumption of coupled mitochondria.
Five experiments were performed at each
concentration. In control experiments
(not shown), addition of malate did not
enhance the rate of oxygen consumption.
that 5-HD is metabolised by the fatty acid oxidation
machinery. 5-HD is activated (Hanley et al. 2002a),
transported into the matrix and efficiently metabolised
via the first two steps of the β-oxidation pathway.
However, in the coupled HAD-thiolase reaction
(penultimate and ultimate steps), the V max with
3,5-dihydroxydecanoyl-CoA was fivefold lower than with
l-3-hydroxydecanoyl-CoA. Two different mechanisms
could be responsible for the slower kinetics observed
with the 5-HD-CoA intermediate. First, the 5-hydroxyl
group may impair the catalytic mechanism of HAD.
Second, the d-isomer product of the thiolase reaction,
d-3-hydroxyoctanoyl-CoA, may inhibit HAD in a
negative-feedback fashion. To shed light on the former
possibility we used modelling, whereas the latter
possibility was tested directly using specially synthesised
isomers.
Our modelling studies of NAD+ and 3,5-DHD-CoA
complexed with HAD suggest that the 5-hydroxyl group,
either in the d or l configuration, can bind at the enzyme
active site with relatively minor structural perturbations.
However, in the d configuration, the hydroxyl group
is wedged between I261 and the critical residue S137,
C© The Physiological Society 2004
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critical in the sense that mutation of S137 to an alanine
virtually abolishes activity (J. J. Barycki and L. J. Banaszak,
unpublished data). On this basis, we infer that the d
configuration (l-3,d-5-dihydroxydecanoyl-CoA derived
from the d-isomer of 5-HD) may be metabolised slowly
by HAD, and thus may be capable of inhibiting the
enzyme in the presence of other substrates. This
interpretation is supported by our finding that
state-3 respiration induced by decanoyl-CoA or
lauryl-CoA was reduced by ≈40% after addition
of 100 µm 5-HD-CoA (Fig. 7). In contrast, the
l configuration (l-3,l-5-dihydroxydecanoyl-CoA) can be
nicely accommodated between V212 and N208, the latter
of which is less critical for activity.
One of the end products of β-oxidation of racemic
5-HD-CoA, l-3-hydroxyoctanoyl-CoA, could bypass
the first two steps of the next cycle and be further
metabolised by the last two enzymes, HAD and
3-ketoacyl-CoA thiolase (Fig. 8). In principle, the
d-isomer should not be metabolised by the enantiospecific
enzyme HAD (Lehninger & Greville, 1953; Wakil &
Mahler, 1954), although molecular modelling suggests
Figure 6. Metabolism of decanoate,
5-HD and their CoA esters by heart
mitochondria
A and B, effects of decanoate or 5-HD on
the rate of oxygen consumption of
coupled rat heart mitochondria in the
presence of 0.5 mM ADP and 0.5 mM
malate, but in the absence of l-carnitine.
Note that 5-HD did not stimulate
respiration. Four experiments were
performed at each concentration. C and
D, effects of decanoyl-CoA and
5-HD-CoA on the rate of oxygen
consumption of coupled mitochondria in
the presence of 0.5 mM ADP, 0.5 mM
malate and 0.2 mM L-carnitine. Three
experiments were performed at each
concentration.
that there is room for d-3-hydroxyl substrates at the
enzyme active site with minor perturbations of the side
chain positions of H158 and N208. In line with the
original studies (Lehninger & Greville, 1953; Wakil &
Mahler, 1954) we found that d-3-hydroxyoctanoyl-CoA
did not act as substrate for HAD and, more
importantly, we showed that this isomer did not
inhibit enzyme activity. Hence, we conclude that
5-hydroxyl- and not the 3-hydroxyl-intermediates of
5-HD-CoA are responsible for the observed slow
kinetics at HAD.
Recently, Lim et al. (2002) observed that 5-HD could
be metabolised by liver and heart mitochondria, but
was a weak substrate compared to decanoate. In addition,
these authors found that 5-HD could not be metabolised
in the presence of CoASH, ATP and l-carnitine, suggesting
that extramitochondrial 5-HD-CoA could not access the
matrix. In contrast, we found that both 5-HD and
5-HD-CoA (in the presence of l-carnitine) could be
metabolised by liver mitochondria. The rates of 5-HD or
5-HD-CoA oxidation were slower than their straight-chain
counterparts (decanoate and decanoyl-CoA). These
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findings indicate that, at least in the liver, mitochondria
can metabolise 5-HD in either case, after activation in
the matrix or after activation at the outer membrane
(Fig. 5). The efficient metabolism of extramitochondrial
5-HD-CoA by liver mitochondria suggests that carnitine
palmitoyltransferases are not rate limiting.
In heart mitochondria, however, 5-HD did not
stimulate respiration (Fig. 6B). The most plausible
interpretation of these data is that 5-HD is a poor substrate
for heart-type matrix acyl-CoA synthetase, an enzyme
which activates selectively short- and medium-chain
fatty acids. However, 5-HD can be activated on the outer
membrane by heart mitochondria (Lim et al. 2002), and
in this form it may be taken up via CPT-I, carnitine
acylcarnitine translocase and CPT-II, and metabolised
(Fig. 6D). The slower metabolism of 5-HD-CoA by heart
mitochondria compared to liver mitochondria may be due
to less-efficient oxidation of 3,5-dihydroxydecanoyl-CoA
by heart-type HAD or, alternatively, heart-type
HAD may be more susceptible to inhibition by
the d-isomer.
Implications for the mechanisms of preconditioning
The current findings, together with recent work (Hanley
et al. 2002a, 2003; Lim et al. 2002), establish that
5-HD is readily activated, taken up into the matrix and
metabolised by the β-oxidation pathway, albeit with slow
kinetics (for overview, see Fig. 8). As a consequence,
application of 5-HD in experimental studies initiates
a complex sequence of biochemical reactions, some of
Figure 7. 5-HD-CoA acts as an inhibitor of fatty acid oxidation in heart mitochondria
The rate of oxygen consumption of coupled heart mitochondria was measured in the presence of 0.5 mM ADP,
0.5 mM malate, 0.2 mM L-carnitine and various added fatty acid substrates. A, addition of 10 µM decanoyl-CoA
(C10-CoA) (n = 4) greatly stimulated respiration compared to control conditions (n = 8). In the presence of 100 µM
5-HD-CoA, the rate of respiration stimulated by decanoyl-CoA was significantly reduced (n = 4). B, lauryl-carnitine
(C12-carn.) strongly stimulated respiration (n = 4) compared to control conditions (n = 8). In the presence of
100 µM 5-HD-CoA this effect was significantly reduced (n = 4). The ordinate in both A and B corresponds to the
maximal rate of oxygen consumption.
which may play a role in the ability of this drug to block
preconditioning. One possibility is that 5-HD, acting as
a weak substrate (Figs 5 and 6), may bypass inhibition
of the electron transport chain at either complex I
or complex II during pharmacological pre-
conditioning (Hanley et al. 2002a,b; Dzeja et al.
2003). The resulting supply of redox equivalents
to the electron transport chain may counteract
inhibition of complex I by volatile anaesthetics or
pinacidil (Berman et al. 1974; Hanley et al. 2002a) or
inhibition of complex II by diazoxide (Schafer et al. 1969;
Ovide-Bordeaux et al. 2000).
Another implication of our study is that
l-3,d-5-dihydroxydecanoyl-CoA may accumulate in
the matrix and create a bottleneck for β-oxidation
of endogenous fatty acids at HAD. In support of this
notion, Lim et al. (2002) reported that 5-HD inhibited
the rate of oxidation of fatty acid substrates in
heart mitochondria. In a precedent case, the potent
3-ketoacyl-CoA thiolase inhibitor trimetazidine (Kantor
et al. 2000) has recently been shown to block ischaemic
and pharmacological preconditioning as effectively as
5-HD (Minners et al. 2000). Interestingly, glibenclamide,
a nonselective KATP channel blocker and inhibitor of
preconditioning, has also been shown to inhibit fatty
acid metabolism, in this case by an inhibitory action at
CPT-I (Lehtihet et al. 2003).
Our results suggest that application of 5-HD may
have profound effects on cardiac energy metabolism
in vivo. (i) Inhibition of β-oxidation of fatty acids by
metabolites of 5-HD at the level of HAD could exacerbate
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the postischaemic accumulation of acyl-CoA esters,
acylcarnitine and fatty acids (van der Vusse et al. 1992;
Zammit, 1999; De Windt et al. 2001; Bartlett & Eaton,
2004). (ii) Mitochondrial accumulation of acyl-CoA
esters could lead to a decrease of free CoA since the
mitochondrial CoA pool is of limited size. This would
inhibit both β-oxidation (at 3-ketoacyl-CoA thiolase) and
glucose oxidation (at pyruvate dehydrogenase) (Randle,
1998; Bartlett & Eaton, 2004). (iii) Accumulation of
5-HD-CoA and other acyl-CoA derivatives, both in
the matrix and in the cytosol, may impair oxidative
phosphorylation by inhibiting adenine nucleotide
translocase (Shrago, 2000). (iv) 5-HD-CoA accumulating
in the cytosol may compete with endogenous acyl-CoA
esters at metabolically important regulatory enzymes
such as acetyl-CoA carboxylase or CPT-I. All of these
effects of 5-HD on cardiac energy metabolism are
potentially detrimental for postischaemic recovery of the
Figure 8. Overview of the metabolism of 5-HD in mitochondria
In both heart and liver mitochondria, 5-HD can be activated at the mitochondrial outer membrane and sub-
sequently enters the matrix via carnitine palmitoyltransferases (CPT-I and CPT-II). In liver, but not in heart, 5-HD
can also be activated in the matrix. The activated form of 5-HD, 5-HD-CoA, is a substrate for the β-oxidation
spiral, which consists of four enzymes: medium-chain acyl-CoA dehydrogenase (MCAD), enoyl-CoA hydratase,
L-3-hydroxyacyl-CoA dehydrogenase (HAD) and 3-ketoacyl-CoA thiolase. Compared to the normal substrate
decanoyl-CoA, the kinetics of 5-HD-CoA metabolism are dramatically slowed at the penultimate step. After
one spiral of β-oxidation, racemic 5-hydroxydecanoyl-CoA would be reduced by two carbons atoms, yielding
racemic 3-hydroxyoctanoyl-CoA, that is, the 5-hydroxyl group becomes a 3-hydroxyl group. The dotted line
indicates that L-3-hydroxyoctanoyl-CoA (the L-isomer) serves as normal substrate for HAD. The other isomer,
D-3-hydroxyoctanoyl-CoA, is neither a substrate nor an inhibitor of HAD. The points in β-oxidation that are slowed
down in the presence of 5-HD are highlighted in red.
heart (van der Vusse et al. 1992; Dyck & Lopaschuk, 2002;
Dyck et al. 2004), and may therefore contribute to the
inhibitory effects of 5-HD on preconditioning.
The complex metabolic effects of 5-HD severely limit
its usefulness as a ‘selective’ blocker of mitochondrial
KATP channels. Furthermore, since their identification
heavily relies on the use of diazoxide as a specific opener
and 5-HD as a specific blocker, the very existence of
mitochondrial KATP channels may be questioned. This
sceptical view is supported by a recent study in which
no changes in mitochondrial matrix volume induced by
diazoxide or 5-HD could be detected (Das et al. 2003).
In conclusion, 5-HD is metabolised by mitochondria
at concentrations employed to block preconditioning.
The novel findings and implications of this
study include those in the following list. (i)
Extramitochondrial 5-HD-CoA can enter the matrix
via carnitine palmitoyltransferases. (ii) The kinetics of
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5-HD-enoyl-CoA and decenoyl-CoA metabolism are
similar at the second step of β-oxidation, catalysed by
enoyl-CoA hydratase. (iii) β-Oxidation of 5-HD-CoA
is slowed at the penultimate step, catalysed by HAD,
which secondarily impairs the metabolism of other fatty
acids. (iv) l-3,d-5-Dihydroxydecanoyl-CoA is mainly
responsible for reducing the catalytic efficiency of HAD.
(v) d-3-Hydroxyoctanoyl-CoA, generated from
β-oxidation of d-5-hydroxydecanoyl-CoA, acts neither
as substrate nor blocks HAD. (vi) Finally, in view of
its complex metabolic effects, 5-HD should no longer
be considered a useful tool for studying the role of
mitochondrial KATP channels in preconditioning.
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Errata
The paper by Hanley et al. (2005) contained a number of errors throughout the paper. These are corrected below.
On page 308, Synthesis and purification of β-oxidation intermediates, the components of Tris buffer solution were
incorrectly listed. The first occurrence of EDTA should have appeared as MgCl2. The sentence should have read:
In brief, acyl-CoA synthetase (EC 6.2.1.3; Sigma) was used to synthesise 5-HD-CoA from 5-HD and CoASH in
tris(hydroxymethyl)aminomethane (Tris) buffer solution containing (mm): 1.2 Na2ATP, 100 Tris, 9.1 MgCl2 and
1.8 EDTA (pH 7.5 with HCl).
On page 314, in the second complete sentence of the page, lauryl-carnitine was incorrectly written as lauryl-CoA. The
sentence should have read:
This interpretation is supported by our finding that state-3 respiration induced by decanoyl-CoA or lauryl-carnitine
was reduced by ≈40% after addition of 100 µm 5-HD-CoA (Fig. 7).
Two references, cited on pages 307 (Garlid et al. 1996) and 309 (Kawaguchi et al. 1981), were omitted from the list. The
full references are given in the Reference list below.
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